Immunomodulators as adjunctive therapy for HIV-1 infection
SL Pett, S Emery - Journal of clinical virology, 2001 - Elsevier
Background: There is renewed interest in the use of immunotherapy as an adjunct to
antiretrovirals (ART) in the treatment of HIV disease. Most work has been performed on
interleukin-2 (IL-2). There is considerable evidence from numerous phase II studies that
intermittent dosing of subcutaneous IL-2 plus antiretroviral therapy (ART) produces a
sustainable rise in the CD4+ T-lymphocyte count which exceeds that which can be achieved
using ART alone, without any adverse effect on plasma HIV RNA. However, the …
antiretrovirals (ART) in the treatment of HIV disease. Most work has been performed on
interleukin-2 (IL-2). There is considerable evidence from numerous phase II studies that
intermittent dosing of subcutaneous IL-2 plus antiretroviral therapy (ART) produces a
sustainable rise in the CD4+ T-lymphocyte count which exceeds that which can be achieved
using ART alone, without any adverse effect on plasma HIV RNA. However, the …